Satellos Bioscience Inc. (MSCLF)
(Delayed Data from OTC)
$0.39 USD
+0.04 (10.86%)
Updated Sep 25, 2024 12:17 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Satellos Bioscience Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 12 | 7 | 5 | 1 | 2 |
Income After Depreciation & Amortization | -12 | -7 | -5 | -1 | -2 |
Non-Operating Income | 1 | -2 | -8 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | -9 | -12 | -1 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -12 | -9 | -12 | -1 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -12 | -9 | -12 | -1 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -12 | -4 | -4 | -1 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 2 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -12 | -7 | -5 | -1 | -2 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 86.41 | 35.68 | 24.08 | 7.69 | 6.12 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.25 | -0.21 | -0.20 | -0.40 |
Diluted Net EPS (GAAP) | -0.13 | -0.25 | -0.51 | -0.15 | -0.30 |
Fiscal Year end for Satellos Bioscience Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 4.88 | 6.12 | 4.57 | 3.35 | 3.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.88 | -6.12 | -4.57 | -3.35 | -3.16 |
Non-Operating Income | 0.47 | 1.00 | -0.24 | 0.72 | 0.19 |
Interest Expense | 0.00 | 0.00 | 0.09 | 0.04 | 0.08 |
Pretax Income | -4.41 | -5.12 | -4.81 | -2.66 | -3.06 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.41 | -5.12 | -4.81 | -2.66 | -3.06 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.41 | -5.12 | -4.81 | -2.66 | -3.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 120.00 | 112.79 | 86.41 | 112.79 | 78.18 |
Diluted EPS Before Non-Recurring Items | -0.04 | -0.04 | -0.04 | -0.02 | -0.04 |
Diluted Net EPS (GAAP) | -0.04 | -0.05 | -0.04 | -0.02 | -0.04 |